Biocompatible protective coating on a medical implant component, an Anti-abrasion medical implant component and process of making the same

TWI945525BActive Publication Date: 2026-11-11INNOJET TECHNOLOGY CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
TW113116330
Authority / Receiving Office
TW · TW
Patent Type
Patents
Current Assignee / Owner
Priority Date
2023-06-21
Filing Date
2024-05-02
Publication Date
2026-11-11
Estimated Expiration
2044-05-01

Smart Images

  • Figure TWG2TB001920270_001
    Figure TWG2TB001920270_001
  • Figure TWG2TB001920270_002
    Figure TWG2TB001920270_002
  • Figure TWG2TB001920270_003
    Figure TWG2TB001920270_003
Patent Text Reader

Abstract

This disclosure relates to a medical implant component comprising a biocompatible protective coating (BPCL) and a method for manufacturing the BPCL and the medical implant component.
Need to check novelty before this filing date? Find Prior Art

Description

Biocompatible Protective Coating Layer on a Medical Implant Component and Method of Manufacturing the Same The present disclosure relates to a medical implant component comprising a biocompatible protective coating layer (BPCL), preferably a silicon nitride (SiN x ) layer, and a method of manufacturing the BPCL and the medical implant component. Medical implant components can be used in various clinical and healthcare applications to provide benefits to physicians, surgeons, registered professional nurses, and patients during or after medical treatment. Thanks to the development of materials science and medical science, the prognosis of patients in need of surgery or medical implants has become increasingly better. For example, artificial joints can improve the motor function of individuals or patients suffering from age-related conditions or diseases and can extend the duration of the body parts of the individuals or patients. To enhance the performance of medical implants, coatings can be applied to their surfaces. However, existing coated medical implants may still exhibit certain deficiencies or drawbacks, such as insufficient biocompatibility, durability, or strength. Additionally, the cost of existing methods for preparing coated medical implants can still be relatively high, and the applicability of the method may be limited in view of the materials of the medical implants. Therefore, there is still a need to develop novel and cost-effective medical implants and methods for their preparation. Accordingly, the present disclosure relates to a medical implant component comprising: (a) a biocompatible substrate, and (b) a biocompatible protective coating layer (BPCL) disposed above or on the substrate; wherein the biocompatible substrate is made of one or more materials selected from the group consisting of biocompatible polymers, biocompatible metals or alloys, and biocompatible ceramics, and wherein the biocompatible protective coating layer (BPCL) has a porosity of less than 1.5%, preferably 1% or less. The present disclosure also relates to a method of manufacturing a medical implant component as described herein, the method comprising the steps of: (i) providing a biocompatible substrate in a deposition chamber; (ii) reducing the pressure in the deposition chamber to less than 0.75 Torr; and (iii) depositing a material of the biocompatible protective coating layer above or on the substrate to form the biocompatible protective layer. In one aspect, the present disclosure provides a medical implant component comprising a biocompatible substrate, a buffer layer on the substrate, and a biocompatible protective coating layer on the buffer layer, i.e., the buffer layer is located between the biocompatible substrate and the biocompatible protective coating layer, wherein the buffer layer is made of an oxide, nitride, or carbide of any one of the following elements: silicon (Si), aluminum (Al), zirconium (Zr), and boron (B). In one aspect, the present disclosure provides a method of manufacturing a medical implant component as described herein, comprising the steps of: (i) Providing a biocompatible substrate in a deposition chamber; (ii) Reducing the pressure in the deposition chamber to less than 0.75 Torr; (ii') Depositing a buffer layer material selected from the group consisting of an oxide, nitride, or carbide of any one of the following elements: silicon (Si), aluminum (Al), zirconium (Zr), and boron (B) to form a buffer layer on the substrate; and (iii') Depositing a material for the biocompatible protective coating layer to form the biocompatible protective coating layer on the buffer layer. In one aspect, the present disclosure provides the medical implant component as part or all of an artificial joint, part or all of an insert associated with an artificial joint, or part or all of a temporary anchoring device. In one aspect, the present disclosure provides a medical implant component, characterized in that it comprises a biocompatible protective coating layer (BPCL) and optionally comprises a buffer layer as described herein. In one embodiment, the biocompatible protective coating layer has a thickness of 0.5 μm to 70 μm, preferably 5 to 30 μm. In any of the foregoing embodiments, the biocompatible protective coating layer (BPCL) has a hardness (Vickers hardness) of at least 800 HV, preferably at most 900 HV, more preferably at most 1200 HV, and most preferably at most 1400 HV. In any of the foregoing embodiments, the biocompatible protective coating layer (BPCL) has a surface roughness of less than 0.25 μm, preferably 0.2 μm or less. In any of the foregoing embodiments, the chemical stoichiometric variation of the atoms of the biocompatible protective coating layer (BPCL) material is less than 20%. In any of the foregoing embodiments, the biocompatible protective coating layer (BPCL) is formed from particles having a D50 in the range of 0.1 μm to 10 μm, preferably in the range of 0.5 μm to 3 μm. In any of the foregoing embodiments, the coefficient of kinetic friction between the medical implant component and other corresponding medical components (such as pads or inserts) ranges from 0.07 to 0.7, preferably from 0.08 to 0.65, more preferably from 0.1 to 0.55. In any of the foregoing embodiments, the biocompatible polymer material is selected from the group consisting of: polytetrafluoroethylene (PTFE), polyetheretherketone (PEEK), polyethylene (PE), polyurethane (PU), and polyvinyl chloride (PVC). In any of the foregoing embodiments, the PE is low density polyethylene (LDPE), high density polyethylene (HDPE), or ultra-high molecular weight polyethylene (UHMWPE). In any of the foregoing embodiments, the biocompatible polymer material has a hardness of at least 400 HV (Vickers hardness), preferably at most 600 HV, more preferably at most 1000 HV; or a Shore D (Shore hardness) of at least 50, preferably at least 55, more preferably at least 60, most preferably at least 65. In any of the foregoing embodiments, the biocompatible metal or alloy is selected from the group consisting of: titanium (Ti) or its alloys, zirconium (Zr) or its alloys, tantalum (Ta) or its alloys, niobium (Nb) or its alloys, stainless steel, cobalt-chromium-molybdenum (Co-Cr-Mo) alloys, and Ti-6Al-4V alloys. In any of the foregoing embodiments, the biocompatible ceramic is selected from the group consisting of oxides, carbides, nitrides, or nitro-carbides of any one of the following elements: silicon (Si), titanium (Ti), tantalum (Ta), tungsten (W), zirconium (Zr), niobium (Nb), chromium (Cr), and aluminum (Al). In any of the foregoing embodiments, the buffer layer has a thickness of 0.5 μm to 10 μm, preferably at least 1 μm. In any of the foregoing embodiments, the adhesion between the buffer layer and the substrate is at least 18 MPa, preferably at least 20 MPa, more preferably at least 25 MPa, most preferably at least 30 MPa. The adhesion can be measured by the Scratch method, Rockwell C tests, or ASTM-C1624. In any of the foregoing embodiments, the deposition of the buffer layer is achieved by ALD, physical vapor deposition (PVD), or chemical vapor deposition (CVD). In any of the foregoing embodiments, the ALD is carried out using a carrier gas selected from the group consisting of: N 2 、O 2, Ar, He, clean dry air (CDA), and any combination thereof. In any of the foregoing embodiments, the AD is carried out at a flow rate of the carrier gas of 180 to 2400 l / hr, preferably 300 to 1500 l / hr. In any of the foregoing embodiments, the temperature of the substrate during the deposition of the buffer layer and / or the biocompatible protective coating layer (BPCL) ranges from 5°C to 50°C, such as at least 15°C, preferably not higher than 35°C. For the convenience of understanding the disclosure herein, the terms used herein are hereby defined below. In the context of this specification and the claims, unless otherwise specifically indicated, the singular forms "a / an" and "the" include plural referents. Any and all examples or illustrative language provided herein (e.g., "such as") are used only to better illustrate the invention and do not limit the scope of the invention, unless otherwise stated. It should be understood that any numerical range described in this specification is intended to include all sub-ranges subsumed therein. For example, the range from "50 to 70°C" includes all sub-ranges and specific values between the stated minimum value of 50°C and the stated maximum value of 70°C, including, for example, from 58°C to 67°C and from 53°C to 62°C, 60°C, or 68°C. Since the disclosed numerical ranges are continuous, they contain each value between the minimum and maximum values. Unless otherwise specified, the multiple numerical ranges indicated in this specification are approximate values. In the present invention, the term "about" refers to an acceptable deviation of the measured value from the established value, which is partly determined by those of ordinary skill in the art depending on how the value is measured or determined. In the present disclosure, the material of the biocompatible protective coating layer includes materials having anti-wear / anti-abrasion properties, including (but not limited to) ceramics such as alumina, silicon nitride, metal nitrides, and any combination thereof, such as silicon nitride (e.g., SiN x , Si 3 N 4 ), alumina (e.g., Al 2 O 3 ), metal nitrides (e.g., TiN). In the present disclosure, the term "silicon nitride" refers to a material having the formula "SiN x ", where x is a value within a reasonable range in view of the chemical bonding theory. In the present disclosure, the term "biocompatible" or "biocompatibility" means being able to come into contact with a living system without causing adverse effects, such as (severe) allergic reactions, damage to cells, tissues or organs in the living body, etc. In the present disclosure, the term "porosity" refers to the degree of pores in a material. In the present disclosure, the term "coefficient of kinetic friction" is the ratio of the frictional force, which can be measured, for example, by a scratch test, to the normal force experienced by the body moving on a dry non-smooth surface. In the present disclosure, the term "aerosol deposition" refers to a deposition method in which aerosol particles themselves are collected or deposited on a solid surface, reducing the concentration of particles in the air. Medical implant components Medical implants may involve metals or alloys (such as CoCrMo, Ti-6Al-4V) or polymeric materials (such as PEEK, UHMWPE) as substrate materials. During long-term use, biochemical corrosion and / or mechanical wear and stress shielding effects of the materials can lead to side effects such as poisoning, allergic reactions, peripheral tissue degradation, etc. Additionally, the hydrophobicity of certain substrate materials will adversely affect the prognosis. To mitigate these drawbacks, it is believed that certain materials such as aluminum oxide (Al 2 O 3 )、Si 3 N 4 、titanium nitride (TiN) exhibit excellent mechanical properties, chemical inertness and biocompatibility and can be used as an anti-wear layer or coating on a substrate material. However, if the protective layer has high porosity, weak adhesion and / or high surface roughness, it can be prone to peeling off, and the resulting particles can cause dislocation or higher wear of the opposing components of the implant. Therefore, in the present disclosure, a medical implant component includes a biocompatible substrate and a biocompatible protective coating layer (BPCL) located above or on the substrate. In one aspect, a medical implant component includes a biocompatible substrate, a buffer layer on the substrate, and a biocompatible protective coating layer (BPCL) on the buffer layer. The biocompatible protective coating layer (BPCL) has low porosity, high adhesion and low surface roughness. Details of the components in the medical implant component are described below. Biocompatible substrate In the present disclosure, once biocompatible substrates known in the art have the desired characteristics, such as sufficient mechanical strength (hardness, firmness, etc.), chemical inertness, biocompatibility, etc., these biocompatible substrates can be used. For example, the materials used to manufacture biocompatible substrates can have a hardness (Vickers hardness) of at least 400 HV or a Shore D (Shore hardness) of at least 50. In various embodiments, the biocompatible substrate can be made of one or more materials selected from the group consisting of biocompatible polymers, biocompatible metals or alloys, and biocompatible ceramics. Examples of biocompatible polymers include, but are not limited to, polyketones such as polyetheretherketone (PEEK); (halogenated) polyolefins such as polyethylene (PE), poly(ethylene-propylene), polytetrafluoroethylene (PTFE), and polyvinyl chloride (PVC); polyurethanes, etc. In various embodiments, the PE is low-density polyethylene (LDPE), high-density polyethylene (HDPE), or ultra-high molecular weight polyethylene (UHMWPE). Examples of biocompatible metals or alloys include, but are not limited to, titanium (Ti) or its alloys, zirconium (Zr) or its alloys, tantalum (Ta) or its alloys, niobium (Nb) or its alloys, stainless steel, cobalt-chromium-molybdenum (Co-Cr-Mo) alloys, and Ti-6Al-4V alloys. Examples of biocompatible ceramics include, but are not limited to, oxides, carbides, nitrides, or nitro-carbides of any of the following elements: silicon (Si), titanium (Ti), tantalum (Ta), tungsten (W), zirconium (Zr), niobium (Nb), chromium (Cr), and aluminum (Al). In one embodiment, the biocompatible substrate has a surface roughness (Ra) of less than 0.3 μm or greater than 0.01 μm. In one embodiment, the biocompatible substrate has a linear thermal expansion coefficient in the range of 6*10 -6 to 18*10 -5 . Biocompatible protective coating layer (BPCL) In the present disclosure, the biocompatible protective coating layer (BPCL) is located on or above the substrate (for example, when there is a buffer layer described below). The biocompatible protective coating layer (BPCL) should have a porosity of less than 1.5%, preferably less than 1.3%, more preferably less than 1%, so that the medical implant can exhibit excellent effects, such as good durability, anti-wear effect, low friction, etc. The low porosity of this layer can be achieved by, for example, the manufacturing method of the medical implant described herein. In one embodiment, the biocompatible protective coating layer (BPCL) has a thickness of 0.5 μm to 70 μm, such as at least 0.5 μm, at least 1 μm, at least 2 μm, at least 3 μm, at least 4 μm, at least 5 μm, at least 6 μm, at least 7 μm, at least 8 μm, at least 9 μm, at least 10 μm, at least 11 μm, at least 12 μm, at least 13 μm, at least 14 μm, at least 15 μm, at least 20 μm, at least 25 μm, at least 30 μm, at least 35 μm; or at most 70 μm, at most 65 μm, at most 60 μm, at most 55 μm, at most 50 μm, at most 45 μm, at most 40 μm; or any reasonable numerical range formed by the above values as endpoints, for example, a thickness of 0.5 μm to 30 μm, 40 μm to 55 μm, 5 μm to 8 μm, etc. In one embodiment, the biocompatible protective coating layer (BPCL) has a hardness (Vickers hardness) of 800 HV to 1400 HV, such as at least 850 HV, at least 900 HV, at least 950 HV, at least 1000 HV, at least 1050 HV, at least 1100 HV; or at most 1350 HV, at most 1300 HV, at most 1250 HV, at most 1200 HV, at most 1150 HV, at most 1100 HV; or any reasonable numerical range formed by the above values as endpoints, for example, a hardness (Vickers hardness) of 900 HV to 1200 HV, 1150 HV to 1350 HV, 800 HV to 1000 HV, etc. In one embodiment, the difference in hardness between the materials of the biocompatible substrate and the biocompatible protective coating layer (BPCL) can be less than 900 HV, such as less than 800 HV, less than 700 HV, less than 600 HV, less than 500 HV, less than 400 HV, less than 300 HV, less than 200 HV, less than 100 HV, less than 50 HV, etc. In one embodiment, the biocompatible protective coating layer (BPCL) has a surface roughness of less than 0.25 μm, such as less than 0.2 μm, less than 0.15 μm, etc. Without being bound by theory, when the surface roughness of the biocompatible protective coating layer (BPCL) is low, the friction between the medical implant and the contact site can be low. In one embodiment, the coefficient of kinetic friction between a medical implant component (specifically, a BPCL) and another corresponding medical component (such as a pad or an insert) ranges from 0.08 to 0.7, for example, less than 0.7, less than 0.65, less than 0.6, less than 0.55, less than 0.5, less than 0.45, less than 0.4, less than 0.3, less than 0.2, less than 0.1; or any reasonable numerical range formed by the above values as endpoints, such as 0.1 to 0.65, 0.1 to 0.55, etc. The average molar ratio between metal atoms and non-metal atoms in the biocompatible protective coating layer (BPCL) (i.e., Al / O, Si / N, Ti / N) can be within a reasonable range based on chemical bonding theory, and the molar ratio deviates from the perfect stoichiometry of the material (for example, about 0.67 for alumina, about 0.75 for silicon nitride, about 1 for titanium nitride, etc.) by no more than 20%. In one embodiment, the biocompatible protective coating layer (BPCL) is formed of particles having a D50 in the range of 0.1 μm to 10 μm, for example, about 0.2 μm, about 0.3 μm, about 0.4 μm, about 0.5 μm, about 0.6 μm, about 0.7 μm, about 0.8 μm, about 0.9 μm, about 1 μm, about 1.5 μm, about 2 μm, about 2.5 μm, about 3 μm, about 3.5 μm, about 4 μm, about 4.5 μm, about 5 μm, about 5.5 μm, about 6 μm, about 6.5 μm, about 7 μm, about 8 μm, about 9 μm, about 10 μm; or any reasonable numerical range formed by the above values as endpoints, such as a D50 of 0.5 μm to 3 μm, 0.8 μm to 5 μm, etc. In one embodiment, the biocompatible protective coating layer (BPCL) has -6 ℃ -1 from 3×10 -6 ℃ -1 to 15×10 -6 ℃ -5 in terms of the coefficient of linear thermal expansion. In one embodiment, the difference between the biocompatible protective coating layer (BPCL) and the biocompatible substrate is in the range of 1.1×10 In one embodiment, the biocompatible protective coating layer (BPCL) has an adhesion to the biocompatible substrate of at least 18 MPa, such as an adhesion of at least 19 MPa, at least 20 MPa, at least 21 MPa, at least 22 MPa, at least 23 MPa, at least 24 MPa, at least 25 MPa, at least 26 MPa, at least 27 MPa, at least 28 MPa; or any reasonable numerical range formed by the above values as endpoints, such as an adhesion of 20 MPa to 28 MPa, etc. The adhesion can be measured by a scratch test, a Rockwell C test, or ASTM-C1624. Buffer layer In one aspect, the medical implant component further includes a buffer layer, which is located on the substrate and between the biocompatible substrate and the biocompatible protective coating layer (BPCL). The buffer layer can assist the adhesion between the biocompatible substrate and the biocompatible protective coating layer (BPCL). Additionally, the buffer layer can allow the surface to exhibit a lower roughness compared to a planar biocompatible substrate. Examples of materials for forming the buffer layer include, but are not limited to, oxides, nitrides, or carbides of any one of the following elements: silicon (Si), aluminum (Al), zirconium (Zr), and boron (B). In one embodiment, the buffer layer has a thickness of 0.5 μm to 10 μm, such as at least 0.5 μm, at least 0.75 μm, at least 1 μm, at least 1.5 μm, at least 2 μm, at least 2.5 μm, at least 3 μm, at least 3.5 μm, at least 4 μm, at least 4.5 μm, at least 5 μm; or at most 10 μm, at most 9.5 μm, at most 9 μm, at most 8.5 μm, at most 8 μm, at most 7.5 μm, at most 7 μm, at most 6.5 μm, at most 6 μm, at most 5.5 μm, at most 5 μm; or any reasonable numerical range formed by the above values as endpoints, such as a thickness of 1 μm to 1.5 μm, 7 μm to 7.5 μm, 2 μm to 6 μm, etc. In one embodiment, the buffer layer has an adhesion to the biocompatible substrate of at least 18 MPa, such as an adhesion of at least 19 MPa, at least 20 MPa, at least 21 MPa, at least 22 MPa, at least 23 MPa, at least 24 MPa, at least 25 MPa, at least 26 MPa, at least 27 MPa, at least 28 MPa; or any reasonable numerical range formed by the above values as endpoints, such as an adhesion of 20 MPa to 28 MPa, etc. In one embodiment, the buffer layer has an adhesion to the biocompatible protective coating layer (BPCL) of at least 18 MPa, such as at least 19 MPa, at least 20 MPa, at least 21 MPa, at least 22 MPa, at least 23 MPa, at least 24 MPa, at least 25 MPa, at least 26 MPa, at least 27 MPa, at least 28 MPa; or any reasonable numerical range formed by the above values as endpoints, such as an adhesion of 20 MPa to 28 MPa, etc. The adhesion can be measured by a scratch test, a Rockwell C test or ASTM-C1624. Application of the medical implant component Due to excellent properties (including but not limited to good durability, good abrasion resistance, high density, low roughness, low porosity, good biocompatibility, etc.), the medical implant component can be used in various applications. Examples of applications include but are not limited to the whole or a part of an artificial joint (e.g., knee joint replacement, hip joint replacement, shoulder joint replacement, radiocarpal joint replacement; cup, head, stem, etc.), an insert or a temporary anchoring device related to an artificial joint (e.g., for orthodontics, surgery, etc., such as a medical locking plate). Manufacturing method of the medical implant component Conventional methods for manufacturing a coating or layer on the substrate of a medical implant component include plasma spraying, physical vapor deposition (PVD), chemical vapor deposition (CVD), spraying methods (thermal or cold spraying), sintering methods, etc. The inventors have found that using aerosol deposition (AD) to deposit a specific ceramic material to form a biocompatible protective coating layer (BPCL) will be beneficial to extend the lifespan of the implant. In short, the AD method can exhibit the following advantages in manufacturing the medical implant components described herein: (1) The deposition rate is higher than that of the PVD / CVD method, which has the benefit of increasing production efficiency; (2) The temperature used for the method of depositing the biocompatible protective coating layer (BPCL) can be significantly lower (e.g., close to room temperature) than the temperature used for PVD / CVD (e.g., higher than 300 °C and even up to 800 °C), thermal spraying or cold spraying (about 300 °C) methods; (3) The requirements for the degree of vacuum are less restrictive than the vacuum requirements for performing the PVD / CVD method; (4) This method can be more easily scaled up compared to the PVD / CVD method; (5) The thickness of the layer can be easily adjusted and can be greater; (6) The adhesion of the deposited layer is significantly higher than that obtained by PVD / CVD, thermal spraying or cold spraying methods; (7) The density and uniformity of the deposited layer can be higher than those obtained by thermal spraying or cold spraying methods; (8) The deposited layer or coating can be nearly a mesh shape, which is difficult when using PVD / CVD, thermal spraying or cold spraying methods; and (9) The cost can be significantly lower than the cost of PVD / CVD, thermal spraying or cold spraying methods. Specifically, a coating layer can be obtained by a plasma spraying method generally used for surface treatment; however, the porosity is too high, the adhesion may be weak and the surface roughness is also high. The sintered coating layer can be dense and have a smooth surface; however, further processing, shaping and polishing can be difficult; additional problems (such as damage to semi-finished products or heterogeneity of the crystalline phase) can occur when scaling up the method due to changes in processing parameters. The PVD / CVD method is mature in this technical field and can provide a coating layer with good characteristics; however, the cost is relatively high and there are inherent limitations, such as the limited thickness of the deposited layer (e.g., up to about 15 μm), degradation of the substrate material due to high processing temperature, etc. In addition, the medium adhesion of the coating layer obtained by the PVD / CVD method may not be sufficient to prevent its abrasion, thus generating particles on the coating layer. The inventors unexpectedly found that the AD method is advantageous for manufacturing medical implant components, specifically the biocompatible protective coating layer (BPCL). Therefore, this disclosure also relates to a method for manufacturing a medical implant component described herein, which comprises the following steps: (i) providing a biocompatible substrate in a deposition chamber; (ii) reducing the pressure in the deposition chamber to less than 0.75 Torr; and (iii) depositing the material of the biocompatible protective coating layer (BPCL) via aerosol deposition (AD) to form a biocompatible protective coating layer (BPCL) above or on the substrate. In one aspect, the present disclosure relates to a method of manufacturing a medical implant component described herein, the method comprising the steps of: (i) providing a biocompatible substrate in a deposition chamber; (ii) reducing the pressure in the deposition chamber to less than 0.75 Torr; (ii') depositing a buffer layer material selected from the group consisting of oxides, nitrides, or carbides of any one of the following elements to form a buffer layer on the substrate: silicon (Si), aluminum (Al), zirconium (Zr), and boron (B); and (iii') depositing a material for a biocompatible protective coating layer via aerosol deposition (AD) to form a biocompatible protective coating layer (BPCL) on the buffer layer. The biocompatible substrate can be the biocompatible substrate described herein. In one embodiment, the biocompatible substrate is made of one or more materials selected from the group consisting of biocompatible polymers, biocompatible metals or alloys, and biocompatible ceramics. In one embodiment, the biocompatible polymer is selected from the group consisting of polyetheretherketone (PEEK), polyethylene (PE), and polyvinyl chloride (PVC). In one embodiment, the PE is low density polyethylene (LDPE), high density polyethylene (HDPE), or ultra-high molecular weight polyethylene (UHMWPE). The AD method can be carried out by known means and equipment. The equipment for carrying out the AD method can include an aerosol generating unit (including, for example, one or more sources of one or more carrier gases, mass flow controllers (MFCs), an aerosol generating chamber), a deposition chamber (equipped with, for example, a nozzle / atomizer, a support plate or stage, etc.), and a vacuum system (such as a pump). Various parameters of the AD method can be adjusted. Examples of parameters include, but are not limited to, the type of one or more carrier gases; flow rate; distance between the nozzle and the substrate support; angle of incidence of the aerosol stream on the substrate; vacuum in the deposition chamber; concentration, particle size, type of one or more materials of the biocompatible protective coating layer in the aerosol stream; temperature in the chamber; temperature of the substrate, etc. Examples of one or more carrier gases include, but are not limited to, nitrogen (N 2 )), oxygen (O 2) Argon (Ar), helium (He), clean dry air (CDA), and any combination and proportion thereof. The flow rate of the carrier gas can be from 180 to 2400 l / hr, for example, about 200 l / hr, about 250 l / hr, about 300 l / hr, about 350 l / hr, about 400 l / hr, about 450 l / hr, about 500 l / hr, about 550 l / hr, about 600 l / hr, about 650 l / hr, about 700 l / hr, about 750 l / hr, about 800 l / hr, about 850 l / hr, about 900 l / hr, about 950 l / hr, about 1000 l / hr, about 1100 l / hr, about 1200 l / hr, about 1300 l / hr, about 1400 l / hr, about 1500 l / hr, about 1600 l / hr, about 1700 l / hr, about 1800 l / hr, about 1900 l / hr, about 2000 l / hr, about 2100 l / hr, about 2200 l / hr, about 2300 l / hr; or any reasonable numerical range formed by the above values as endpoints, for example, 500 l / hr to 650 l / hr, 300 to 1500 l / hr, etc. The temperature (of the biocompatible substrate) during the AD method can be controlled within the range of 5°C to 50°C, for example, in the range of 15°C to 45°C, and preferably not higher than 35°C. The material powder can have a D50 in the range of 0.5 μm to 10 μm, for example, about 0.2 μm, about 0.3 μm, about 0.4 μm, about 0.5 μm, about 0.6 μm, about 0.7 μm, about 0.8 μm, about 0.9 μm, about 1 μm, about 1.5 μm, about 2 μm, about 2.5 μm, about 3 μm, about 3.5 μm, about 4 μm, about 4.5 μm, about 5 μm, about 5.5 μm, about 6 μm, about 6.5 μm, about 7 μm, about 8 μm, about 9 μm, about 10 μm; or any reasonable numerical range formed by the above values as endpoints, for example, 0.5 μm to 3 μm, 0.8 μm to 5 μm, etc. The raw material can be subjected to one or more pre-treatments, such as milling, sieving, etc., to provide one or more materials for deposition via the AD method. The buffer layer can be deposited via the AD method described herein or physical vapor deposition (PVD) or chemical vapor deposition (CVD) methods. Examples of PVD / CVD methods include but are not limited to sputtering PVD (using DC or RF sputtering devices), laser-assisted PVD (LA-PVD), low-pressure CVD (LPCVD), metal-organic CVD (MOCVD), plasma-enhanced CVD (PECVD), etc. Preferably, the buffer layer is produced via the AD method. Once the deposition of the biocompatible protective coating layer (BPCL) is completed, the semi-finished product can undergo post-treatment such as cleaning, shaping, etc. Example The following examples are provided to make it easier for those of ordinary skill in the art related to the present invention to understand the present invention, but are not intended to limit the scope of the present invention. Materials, Methods and Test Models The materials for the biocompatible protective layer include Si available from Sigma-Aldrich 3 N 4 Al 2 O 3 TiN (4N purity). The CoCrMo alloy is available from DePuy Synthes. If needed, the materials can be further processed via UPE - Celanese GUR@1020 - E. The porosity of the layer can be measured by Hitachi S - 4300 FE - SEM. The thickness and roughness can be measured by KLA - D500. The adhesion can be evaluated by a Helmut - fisher Adhesion tester ST30 or Mitutoyo HR600 (Rockwell C indenter). Example 1 The CoCrMo alloy is used as the substrate material and is cleaned and washed to remove impurities, and then dried before being placed on a support in the chamber of the AD device. The temperature, vacuum and other necessary parameters are set. The material powders (i.e., aluminum, silicon nitride, titanium nitride) are loaded into the aerosol generation unit. Then, the AD deposition of the materials is started. After the deposition of the biocompatible protective coating layer (BPCL) is completed, the vacuum is broken and the semi-finished product is post-treated to obtain an exemplary medical implant component. Images of exemplary products (knee joint, screw) are shown in Figure 2. Example 2 The CoCrMo alloy is used as a substrate material and is cleaned and washed to remove impurities, and then dried before being placed on a support in the chamber of an AD device. The temperature, vacuum degree, and other necessary parameters are set. In this case, the biocompatible protective coating layer (BPCL) is formed of silicon nitride, and titanium nitride is used as the material for forming the buffer layer. The titanium nitride powder is loaded into an independent aerosol generation unit. Then, the AD deposition of the buffer layer material is started. After the deposition of the buffer layer is completed, the AD deposition of silicon nitride is started. After the deposition of the biocompatible protective coating layer (BPCL) is completed, the vacuum is broken and the semi-finished product is post-treated to obtain an exemplary medical implant component. Example 3 ( Comparative ) A medical implant component is provided by magnetron sputtering a silicon nitride layer on a CoCrMo substrate. Example 4 ( Comparative ) A medical implant component is provided by magnetron sputtering chromium nitride as a buffer layer on a CoCrMo substrate and magnetron sputtering a silicon nitride layer on the buffer layer. Example 5 The characteristics of the medical implant components described in Examples 1 to 4 are listed in Table 1: Table 1 Example 6 Based on SEM technology, the microscopic behavior and characteristics are studied. Figures 3A to 3C show the SEM images of the medical implant component described in Example 1, the medical implant component with a coating layer obtained by APS, and the medical implant component with a coating layer obtained by PVD. Apparently, the biocompatible protective coating layer (BPCL) is embedded in the substrate (or the buffer layer, if any), specifically forming chemical bonds, and the attached area therebetween is significantly increased, and thus the attachment is firm. In contrast, there may be a space or gap between the conventional coating layer (such as obtained by APS or PVD) and its substrate. There is porosity in the coating layer (see Figure 3B), while there is no coating layer embedded in the substrate (see Figure 3C). Example 7 Wear tests were conducted on a medical implant assembly (knee joint) prepared by the method described in Example 1 and a conventional knee joint for comparison. The wear tests were carried out and the conditions and results are summarized in Table 2 below. Specifically, under a specified normal force, the product was tested using an abrader that traveled a specified distance at a specified diameter. The wear amount was calculated based on the travel diameter and the wear area. Optical images of the knee joint (Example 1), and SEM images of the knee joint (Example 1) and the conventional knee joint (without a coating layer or coated via PVD) are shown in Figures 4A to 4D. Apparently, the product of the present invention exhibits characteristics superior to those of the conventional product (specifically, anti-wear characteristics), such as significantly smaller wear amounts under higher normal force and travel distance tests (see, Sample A versus Sample B), and higher wear resistance (see, Sample A versus Sample C, similar wear amounts under more severe test conditions). Table 2 SEM images of the bottom (Figure 5A) and the opposite side (Figures 5B and 5C) of the screw after the wear test are also provided, which clearly show minimal wear of the coating layer after the wear test. The present invention clearly exhibits an effect superior to that of existing medical implant assemblies. Specifically, the adhesion between the biocompatible protective coating layer and the substrate is significantly enhanced. Additionally, when using other deposition techniques such as magnetron sputtering, the deposition rate may be limited by the nature of the technique; even when using a higher rate, the desired characteristics such as low porosity, low surface roughness, high adhesion, etc. cannot be provided. Without being bound by theory, a higher deposition rate of materials such as via magnetron sputtering may result in a higher defect density, higher porosity, higher roughness, etc. in the deposited layer. Additionally, when the deposition rate increases, the temperature of the substrate being deposited may increase, which may have an undesired effect or impact on the deposited layer. Those of ordinary skill in the art of the present invention should understand that changes and modifications can be made to the teachings and disclosures of the present invention without departing from the spirit and scope of the present application. Based on the above, the present application intends to cover any changes and modifications thereof, provided that the changes or modifications or their equivalents fall within the scope defined by the appended claims for patent. Figure 1 shows an illustrative scheme of the manufacturing method of the medical implant of the present invention. Figure 2 shows exemplary products (knee joint and screw). Figures 3A to 3C show the microscopic behavior and characteristics of the medical implant. Figures 4A to 4D show the optical or SEM images of the medical implant after the wear test. Figures 5A to 5C show the SEM images of the screw of the present invention after the wear test.

Claims

1. An anti-wear medical implant component comprising: (a) a biocompatible substrate, and (b) a biocompatible protective coating (BPCL) disposed above or on the substrate, wherein the biocompatible protective coating (BPCL) has a surface roughness of less than 0.25 μm; wherein the biocompatible substrate is made of one or more materials selected from the group consisting of: biocompatible polymers, biocompatible metals or alloys, and biocompatible ceramics, and wherein the biocompatible protective coating (BPCL) has a porosity of less than 1.5%.

2. The wear-resistant medical implant component of claim 1, wherein the biocompatible protective coating (BPCL) is formed of one or more materials selected from the group consisting of: alumina, silicon nitride, metal nitrides and any combination thereof.

3. The abrasion-resistant medical implant component as claimed in claim 1 or 2, wherein the biocompatible protective coating (BPCL) has a thickness of 0.5 μm to 70 μm.

4. The wear-resistant medical implant component as claimed in claim 1 or 2, wherein the biocompatible protective coating (BPCL) has a hardness of 800 HV to 1400 HV (Vickers hardness).

5. For the wear-resistant medical implant components of claim 1 or 2, the stoichiometric change of atoms in the biocompatible protective coating (BPCL) material is less than 20%.

6. The abrasion-resistant medical implant assembly of claim 1 or 2, wherein the biocompatible protective coating (BPCL) is formed of particles having a D50 in the range of 0.1 μm to 10 μm.

7. The wear-resistant medical implant component of claim 1 or 2, wherein the biocompatible polymeric material is selected from the group consisting of: polyketides, (halogenated) polyolefins and polyurethanes.

8. The wear-resistant medical implant component as claimed in claim 1 or 2, wherein the biocompatible polymeric material is selected from the group consisting of: polyetheretherketone (PEEK), polyethylene (PE), polytetrafluoroethylene (PTFE), polyvinyl chloride (PVC), and polyurethane (PU).

9. The abrasion-resistant medical implant component as claimed in claim 8, wherein the PE is low-density polyethylene (LDPE), high-density polyethylene (HDPE), or ultra-high molecular weight polyethylene (UHMWPE).

10. The wear-resistant medical implant component of claim 1 or 2, wherein the biocompatible polymeric material has a hardness of at least 400 HV (Vickers hardness) or at least 50 Shore D (Shore hardness).

11. The wear-resistant medical implant component as claimed in claim 1 or 2, wherein the biocompatible metal or alloy is selected from the group consisting of: titanium (Ti) or alloys thereof, zirconium (Zr) or alloys thereof, tantalum (Ta) or alloys thereof, niobium (Nb) or alloys thereof, stainless steel, cobalt-chromium-molybdenum (Co-Cr-Mo) alloys and Ti-6Al-4V alloys.

12. The wear-resistant medical implant component as claimed in claim 1 or 2, wherein the biocompatible ceramic is selected from the group consisting of oxides, carbides, nitrides or nitrocarbides of any of the following elements: silicon (Si), titanium (Ti), tantalum (Ta), tungsten (W), zirconium (Zr), niobium (Nb), chromium (Cr) and aluminum (Al).

13. The wear-resistant medical implant assembly of claim 1 or 2 further comprises a buffer layer, wherein the buffer layer is located between the biocompatible substrate and the biocompatible protective coating layer (BPCL), and wherein the buffer layer is made of an oxide, nitride or carbide of any of the following elements: silicon (Si), aluminum (Al), zirconium (Zr) and boron (B).

14. The abrasion-resistant medical implant assembly of claim 13, wherein the buffer layer has a thickness of 0.5 μm to 10 μm.

15. The medical implant assembly as claimed in claim 13, wherein the adhesion between the buffer layer and the substrate is at least 18 MPa.

16. The wear-resistant medical implant component as claimed in claim 1 or 2 is part or in whole of an artificial joint, part or in whole of an insert associated with an artificial joint, or part or in whole of a temporary anchoring device.

17. A method of manufacturing an anti-wear medical implant component as claimed in any one of claims 1 to 16, comprising the steps of: (i) providing a biocompatible substrate in a deposition chamber; (ii) reducing the pressure in the deposition chamber to less than 0.75 Torr; and (iii) depositing a biocompatible protective coating (BPCL) material via aerosol deposition (AD) to form the biocompatible protective coating (BPCL) over or on the substrate.

18. The method of claim 17, further comprising a step (ii') following step (ii): (ii') depositing a buffer layer material selected from the group consisting of oxides, nitrides or carbides of any of the following elements to form a buffer layer on the substrate: silicon (Si), aluminum (Al), zirconium (Zr) and boron (B), wherein step (iii) is step (iii'): (iii') depositing a biocompatible protective coating (BPCL) material via aerosol deposition (AD) to form the biocompatible protective coating (BPCL) over or on the buffer layer.

19. The method of claim 18, wherein the deposition of the buffer layer is achieved via AD, physical vapor deposition (PVD) or chemical vapor deposition (CVD).

20. The method of any one of claims 17 to 19, wherein the AD is carried out using a carrier gas selected from the group consisting of: N2, O2, Ar, He, clean dry air (CDA) and any combination thereof.

21. The method of any one of claims 17 to 19, wherein the AD is carried out at a carrier gas flow rate of 180 to 2400 l / hr.

22. The method of any one of claims 17 to 19, wherein the temperature of the substrate during the deposition is in the range of 5°C to 50°C.

23. The method of any one of claims 17 to 19, wherein the biocompatible protective coating (BPCL) material is used in the form of a powder having a D50 in the range of 0.5 μm to 10 μm.

24. The method of any one of claims 17 to 19, wherein the biocompatible substrate is made of one or more materials selected from the group consisting of: biocompatible polymeric materials, biocompatible metals or alloys, and biocompatible ceramics.

25. The method of claim 24, wherein the biocompatible polymeric material is selected from the group consisting of: polyketides, (halogenated) polyolefins and polyurethanes.

26. The method of any one of claims 17 to 19, wherein the biocompatible polymeric material is selected from the group consisting of: polyetheretherketone (PEEK), polyethylene (PE), polytetrafluoroethylene (PTFE), polyvinyl chloride (PVC), and polyurethane (PU).

27. The method of claim 26, wherein the PE is low-density polyethylene (LDPE), high-density polyethylene (HDPE), or ultra-high molecular weight polyethylene (UHMWPE).

28. An anti-wear medical implant component, characterized in that it comprises a biocompatible protective coating (BPCL) and, where appropriate, a buffer layer, wherein the biocompatible protective coating (BPCL) has a porosity of less than 1.5% and a surface roughness of less than 0.25 μm.

Citation Information

Patent Citations

  • Antibacterial biomedical implants and associated materials, apparatus, and methods

    CN110461378A

  • PEEK surface hot-pressing method nanometer morphology modification method, PEEK material obtained through modification and application of PEEK material

    CN116162273A

  • Composite prosthetic surfaces

    TW201613654A